Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 53

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 53
---
life sciences industry. We completed our initial public offering in Israel in February 2007 and our ordinary shares are traded on the
TASE under the symbol “ BLRX.” In July 2011, we listed our ADSs on Nasdaq and they are traded under the symbol “ BLRX.”

In March 2017, we acquired Agalimmune a private U. K.-based company and
intend to either transfer ownership of Agalimmune to a third party or liquidate it during 2025.

Our capital expenditures for the year ended December 31, 2024 were
immaterial and were $0.3 million for each of the years ended December 31, 2022 and 2023. Our current capital expenditures involve acquisitions
of laboratory equipment, computers and communications equipment.

30

The SEC maintains an Internet site that contains reports, proxy
and information statements, and other information regarding issuers like BioLineRx that file electronically with the SEC. The address
of that site is www. sec. gov. We maintain a corporate
website at www. biolinerx. comInformation contained
on or accessible through our website is not a part of this Annual Report on Form 20-F, and the inclusion of our website address herein
is an inactive textual reference only.

We use our website ( http://www. biolinerx. com)
as a channel of distribution of Company information. The information we post through this channel may be deemed material. Accordingly,
investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
The contents of our website are not, however, a part of this Annual Report on Form 20-F.

B. Business Overview

We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. Our first approved product, APHEXDA® (motixafortide), a novel peptide for the treatment of stem-cell
mobilization and solid tumors, with an indication in the United States for stem cell mobilization for autologous transplantation
in multiple myeloma, is being developed and commercialized by Ayrmid (globally, excluding Asia) and Gloria (in Asia). We are also advancing
the development of motixafortide for patients with pancreatic cancer and other solid tumors.

Following the out-licensing of APHEXDA (motixafortide) to Ayrmid
and Gloria, we have refocused our operations on development activities